Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Over 200 delegates travelled from more than 50 countries to attend the first ever conference on Medicine Quality and Public Health (MQPH 2018) in Oxford from 23-28 Sept. The conference, at Keble College, brought together experts in pharmacy, public health, chemistry, law, sociology, governance and ethics, from medicines regulatory authorities, academia, pharmaceutical industry, NGOs, and international organisations.

MQPH discussion panel, with Celine Caillet, Serena Vickers, Muhammad Zaman, Richard Jahnke

The many conference partners included the US Pharmacopeia (USP), WHO, Wellcome and the Concept Foundation. The latest evidence on the prevention, detection and response to substandard, falsified and unregulated medicines was discussed along with inspiring collaborations and strategies to tackle this global challenge.

Opening speakers Dr Suzanne Hill, Director of the Essential Medicines and Health Products Department of the World Health Organization (WHO), Prof Louise Richardson, Vice-Chancellor of the University of Oxford, Ms Agnes Sitta Kijo, Acting Director General of the Tanzanian Food and Drugs Authority (TFDA), and Prof Sir Nicholas White, Chairman of the MORU Tropical Health Network, called for collaborative efforts beyond geographic borders and sectoral divisions to more urgently intervene to address the serious public health problem of substandard and falsified medical products.

A brief Oxford Statement, under the auspices of the conference and the Let's Demand Medicines We Can Trust campaign, was released 14 Nov 2018. Prof Paul Newton, LOMWRU Director and Head of the IDDO Medicine Quality Group explained: “The conference consensus statement outlines the key opportunities and priority ‘next steps’ to tackle poor quality medicines. We hope to organize many more opportunities to collaborate and make a real difference to the lives of those affected by this unacceptable global health challenge.”

The full story is available on the Oxford Tropical Medicine website

Similar stories

Antimalarial chemoprophylaxis for forest goers could help accelerate malaria elimination in Cambodia

Giving people antimalarials during and after visiting the forest reduced their risk of contracting malaria 6-fold, and could be the missing piece towards eliminating malaria in Asia-Pacific and South America, say Mahidol and Oxford University researchers in a study published in The Lancet Infectious Diseases.

A new WWARN study supports safety of WHO recommended malaria treatment to advance elimination and reduce spread of artemisinin resistance

A new WWARN study, published in BMC Medicine, supports a World Health Organization (WHO) recommendation that a single primaquine target dose of 0.25 mg/kg is generally safe and well tolerated when given together with an ACT to treat malaria.

Routine surveillance data can provide an early warning system for antimalarial resistance in pre-elimination areas in Africa

In the first published study of its kind, a new WWARN paper in the Malaria Journal has created near-real-time maps to support antimalarial drug resistance monitoring, using routine malaria surveillance data and individually patient linked data on molecular markers of antimalarial drug resistance.

Four CTMGH researchers awarded full professorships

We are delighted to announce that four of our researchers have been awarded the title of Professor, in recognition of their research achievements, contribution to teaching, and contribution to the general work of the Nuffield Department of Medicine, University of Oxford.

INTERBIO-21st study findings could help predict infants at risk of obesity

Fetal abdomen growth and the mother’s blood fat metabolites very early in pregnancy influence a child’s weight, body fat, vision and neurodevelopment at 2 years of age

Oxford University launch new clinical trial to test a treatment for monkeypox

The team behind the world-leading RECOVERY trial of COVID-19 treatments are leading a new study investigating a potential treatment for people who have been diagnosed with monkeypox. The National Institute for Health and Care Research (NIHR) has commissioned and funded the study. The first patients have now been recruited.